Abstract： Objective To investigate the clinical value of keluoxin capsules combined with pancreatic kininogenase in the treatment of diabetic nephropathy(DN).Methods A total of 162 patients with DN admitted to The 988th Hospital of the PLA Joint Logistic Support Force from January 2021 to July 2023 were retrospectively selected for study and analysis,and divided into control group(n=81)and observation group(n=81)according to different treatment regimens.The control group was treated with pancreatic kininogenase,and the observation group was treated with keluoxin capsules combined with pancreatic kininogenase.The blood glucose-related indicators(HbA1c,2 hPG,FBG),renal function indicators(24 hUTP,Cys C,β2-MG),renal fibrosis indicators(VEGF,Hcy),and oxidative stress indicators(GSH-Px,SOD)were compared between the two groups,as well as the incidence of adverse reactions.Results After 2 months of treatment,the levels of HbA1c,FBG and 2 hPG in observation group were lower than those in control group(P<0.05);24 hUTP,CysC and β2-MG levels in observation group were lower than those in control group(P<0.05);the levels of VEGF and Hcy in observation group were lower than those in control group(P<0.05);the levels of GSH-PX and SOD in observation group were higher than those in control group(P<0.05).There was no significant difference in the total incidence of adverse reactions between the observation group and the control group(P>0.05).Conclusion Keluoxin capsules combined with pancreatic kininogenase can effectively reduce blood glucose level,inhibit oxidative stress reaction,alleviate renal fibrosis injury and improve renal function in patients with DN,and the drug safety is guaranteed.